L. Roy Papp & Associates LLP Has $385,000 Position in Zoetis Inc. (NYSE:ZTS)

L. Roy Papp & Associates LLP lifted its position in Zoetis Inc. (NYSE:ZTS) by 2.8% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,221 shares of the company’s stock after buying an additional 60 shares during the period. L. Roy Papp & Associates LLP’s holdings in Zoetis were worth $385,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of ZTS. Hohimer Wealth Management LLC raised its stake in shares of Zoetis by 1.2% in the 4th quarter. Hohimer Wealth Management LLC now owns 4,386 shares of the company’s stock valued at $866,000 after purchasing an additional 52 shares during the period. Forum Financial Management LP lifted its stake in Zoetis by 0.8% in the 4th quarter. Forum Financial Management LP now owns 7,386 shares of the company’s stock valued at $1,458,000 after purchasing an additional 56 shares during the last quarter. Angeles Wealth Management LLC boosted its stake in shares of Zoetis by 3.5% during the 4th quarter. Angeles Wealth Management LLC now owns 1,640 shares of the company’s stock worth $324,000 after acquiring an additional 56 shares during the period. Prossimo Advisors LLC boosted its position in Zoetis by 1.7% during the fourth quarter. Prossimo Advisors LLC now owns 3,498 shares of the company’s stock worth $690,000 after purchasing an additional 57 shares during the period. Finally, Forza Wealth Management LLC raised its holdings in Zoetis by 1.8% in the 2nd quarter. Forza Wealth Management LLC now owns 3,313 shares of the company’s stock valued at $574,000 after acquiring an additional 58 shares during the period. 92.80% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on ZTS. HSBC cut their price target on Zoetis from $230.00 to $225.00 and set a “buy” rating for the company in a research note on Wednesday, May 8th. Argus raised Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. Stifel Nicolaus upped their price objective on shares of Zoetis from $180.00 to $200.00 and gave the company a “buy” rating in a research note on Monday, August 5th. Piper Sandler lifted their target price on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. Finally, The Goldman Sachs Group dropped their price target on Zoetis from $223.00 to $196.00 and set a “buy” rating on the stock in a research note on Monday, May 6th. Nine equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $217.11.

Zoetis Stock Performance

Shares of NYSE ZTS traded down $1.27 during midday trading on Friday, reaching $180.90. The company’s stock had a trading volume of 1,247,398 shares, compared to its average volume of 2,714,365. The stock has a market capitalization of $82.54 billion, a P/E ratio of 34.82, a PEG ratio of 2.81 and a beta of 0.86. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.45 and a quick ratio of 2.09. The firm has a 50 day moving average price of $178.35 and a 200-day moving average price of $175.15. Zoetis Inc. has a 12-month low of $144.80 and a 12-month high of $201.92.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Tuesday, August 6th. The company reported $1.56 earnings per share for the quarter, topping analysts’ consensus estimates of $1.49 by $0.07. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The company had revenue of $2.36 billion for the quarter, compared to the consensus estimate of $2.31 billion. During the same period in the previous year, the firm earned $1.41 EPS. The firm’s quarterly revenue was up 8.3% on a year-over-year basis. As a group, equities analysts predict that Zoetis Inc. will post 5.84 earnings per share for the current year.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.